Brief: Lantern Pharma Receives Pre-IND Feedback From FDA, Clearing Path For Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
17/01/2023 15:14
Jan 17 (Reuters) - Lantern Pharma Inc. LTRN.O :
* LANTERN PHARMA RECEIVES PRE-IND FEEDBACK FROM THE FDA,
CLEARING
A PATH FOR DRUG CANDIDATE LP-184’S PHASE 1 CLINICAL TRIAL IN Q2
2023
Source text for Eikon: ID:nBwgqLRNa
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview